Abstract
Started in 1963 by Robert Guthrie, newborn screening (NBS) is considered to be one of the great public health achievements. Its original goal was to screen newborns for conditions that could benefit from presymptomatic treatment, thereby reducing associated morbidity and mortality. With advances in technology, the number of disorders included in NBS programs increased. Pompe disease is a good candidate for NBS. Because decisions regarding which diseases should be included in NBS panels are made regionally and locally, programs and efforts for NBS for Pompe disease have been inconsistent both in the United States and globally. In this article, published in the "Newborn Screening, Diagnosis, and Treatment for Pompe Disease" guidance supplement, the Pompe Disease Newborn Screening Working Group, an international group of experts in both NBS and Pompe disease, review the methods used for NBS for Pompe disease and summarize results of current and ongoing NBS programs in the United States and other countries. Challenges and potential drawbacks associated with NBS also are discussed.
Highlights
The effectiveness of newborn screening Recommended Uniform Screening Panel (RUSP) (NBS) in LSDs to improve outcomes was first demonstrated in Pompe disease
Results of NBS have been summarized for 473 738 newborn samples screened for Pompe disease
Two assays were performed at screening: acid α-glucosidase infantile-onset Pompe disease (IOPD) (GAA) activity measured at pH 3.8 in the presence of acarbose and neutral α-glucosidase (NAG) activity measured at pH 7.0 without acarbose
Summary
Ronald Scott, MD,b Roberto Giugliani, MD, PhD,c on behalf of the Pompe Disease Newborn Screening Working Group abstract. Started in 1963 by Robert Guthrie, newborn screening (NBS) is considered to be one of the great public health achievements. Because decisions regarding which diseases should be included in NBS panels are made regionally and locally, programs and efforts for NBS for Pompe disease have been inconsistent both in the United States and globally. In this article, published in the “Newborn Screening, Diagnosis, and Treatment for Pompe Disease” guidance supplement, the Pompe Disease Newborn Screening Working Group, an international group of experts in both NBS and Pompe disease, review the methods used for NBS for Pompe disease and summarize results of current and ongoing NBS programs in the United States and other countries. The guidelines/recommendations in this article are not American Academy of Pediatrics policy, and publication does not imply endorsement. 2017; 140(s1):e20160280C
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
